91¹ú²ú¾«Æ·

Research


CAR-T Toxicities Consortium

The Chimeric Antigen Receptor (CAR) T-Cell Toxicities Consortium unites investigators from scientific and medical associations, government agencies, and registries, to address emerging toxicities associated with the application of CAR T-cell therapies.

A diagram depicting CAR-T processes

Goals and Objectives

The consortium, consisting of representatives from scientific and medical associations, U.S. Food and Drug Administration (FDA) and the Center for International Blood and Marrow Transplant Research (CIBMTR) working together, will address urgent needs related to emerging CAR-T adverse events and identify opportunities to address the following areas:

  1. Increasing investigators’ understanding of the molecular mechanisms surrounding these toxicities and the role conditioning regimens could play in their onset.  
  2. Exploring ways to effectively report and catalog these toxicities to inform future research.  
  3. Developing educational resources for clinicians to inform toxicity management approaches.  
  4. Informing regulatory agencies on the challenges and recent developments in the field surrounding this topic. 

Current Focus

The consortium is expected to convene on a bi-monthly basis (i.e., every other month) with its first order of business being to conduct a landscape analysis of the field. Based on its assessment, it will then ascertain and develop resources to address important gaps. 

Consortium Members

Members consist of individuals who have expertise in CAR-T cells and the ability to carry forward recommendations from this consortium to their respective organizations.

91¹ú²ú¾«Æ·

Nirali N. Shah, MD, MHSc, (Chair)

Robert S Negrin, MD, PhD, (Vice Chair)

Alice Kuaban, MS, (Staff Liason)

American Association for Cancer Research

Helen E. Heslop, MD, DSc (Hon)

Nikhil C. Munshi, MD

American College of Rheumatology 

Maximilian F. Konig, MD, DSc (Hon)

C. Thomas Appleton, MD, PhD, FRCPC


American Society of Gene and Cell Therapies

Isabelle Riviere, PhD

Marco Davila, MD, PhD

91¹ú²ú¾«Æ· Collaborative

Saad Usmani, MD, MBA, FACP, FASCO

William Wood, MD, MPH

American Society for Transplantation and Cellular Therapies 

Frederick Locke, MD

Marcela Maus, MD, PhD

Center for International Blood and Marrow Transplant Research

Marcelo Pasquini, MD, MS


Society for Immunotherapy of
Cancer

Kristen Hege, MD

Sarah Warren, PhD


Food and Drug Administration 

Nicole Verdun, MD



International Society for Cell and Gene Therapy 

Bruce Levine, PhD

Jaap Jan Boelens, MD, PhD


 

 

 

Questions?

For more information on the CAR-T Toxicities Consortium, please contact ASH’s Director of Scientific Affairs, Alice Kuaban, MS at [email protected].